Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis.
Mesic A, Spina A, Mar HT, Thit P, Decroo T, Lenglet A, Thandar MP, Thwe TT, Kyaw AA, Homan T, Sangma M, Kremer R, Grieg J, Piriou E, Ritmeijer K, Van Olmen J, Lynen L, Oo HN
To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.
Schlotthauer F, McGregor J, Drummer HE
Hepatitis CRole of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia.
Stuart RM, Abeysuriya RG, Kerr CC, Mistry D, Klein DJ, Gray RT, Hellard M, Scott N
COVID-19Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Li Z, Wijesundara DK, Ellenberg P, Lackenby JA, Cheung STM, Modhiran N, Avumegah MS, Henderson CL, Hoger K, Griffin P, Bennet J, Hensen L, Zhang W, Nguyen THO, Marrero-Hernandez S, Selva KJ, Chung AW, Tran MH, Tapley P, Barnes J, Reading PC, Nicholson S, Corby S, Holgate T, Wines BD, Hogarth PM, Kedzierska K, Purcell DFJ, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP
COVID-19